AUPH
Aurinia Pharmaceuticals Inc. · Healthcare · Biotechnology
Last
$14.17
+$0.20 (+1.43%) 4:00 PM ET
After hours $14.38 +$0.21 (+1.48%) 8:32 AM ET
Prev close $13.97
Open $13.92
Day high $14.18
Day low $13.53
Volume 1,799,450
Avg vol 897,706
Mkt cap
$1.87B
P/E ratio
25.30
FY Revenue
$265.81M
EPS
0.56
Gross Margin
88.93%
Sector
Healthcare
AI report sections
AUPH
Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals exhibits solid profitability, free cash flow generation, and balance sheet liquidity alongside a 12‑month price gain of 93.4% that places the stock near the upper end of its 52‑week range. Technical signals are more mixed in the near term, with price slightly below the 50‑day moving average and modestly negative 1‑month returns but several short‑term bullish pattern triggers. Valuation multiples appear elevated relative to revenue and earnings while operating cash flow growth and margins remain comparatively strong, and short interest is moderate with days to cover above seven.
AI summarized at 2:08 PM ET, 2026-02-03
AI summary scores
INTRADAY: 56 SWING: 62 LONG: 74
Volume vs average
Intraday (cumulative)
+182% (Above avg)
Vol/Avg: 2.82×
RSI
36.88 (Weak)
Weak (30–40)
MACD momentum
Intraday
+0.02 (Strong)
MACD: 0.03 Signal: 0.01
Short-Term
+0.01 (Strong)
MACD: -0.19 Signal: -0.20
Long-Term
+0.01 (Strong)
MACD: -0.40 Signal: -0.41
Intraday trend score 53.52

Latest news

AUPH 12 articles Positive: 2 Neutral: 0 Negative: 0
Positive GlobeNewswire Inc. • Spherix Global Insights
New American College of Rheumatology Guidelines for Lupus Nephritis Recommend Triple Therapy, Highlighting a Shift in Current Treatment Practices, According to Spherix Global Insights

The American College of Rheumatology has updated its guidelines for treating lupus nephritis, recommending early use of triple therapy (mycophenolate mofetil, glucocorticoids, and either Benlysta or a calcineurin inhibitor). However, current practice often delays initiating triple therapy until initial treatment failure.

GSK AUPH lupus nephritis American College of Rheumatology triple therapy Benlysta Lupkynis
Sentiment note

The article also mentions the approval of Aurinia's Lupkynis for the treatment of lupus nephritis, which is seen as a positive advancement in the management of the condition.

Positive GlobeNewswire Inc. • American Kidney Fund
Corporate and Individual Donations Provide Much-Needed Support to Kidney Patients Impacted by Hurricane Helene Through the American Kidney Fund’s Disaster Relief Program

The American Kidney Fund's Disaster Relief Program is providing emergency financial assistance to dialysis and recent transplant patients in areas affected by Hurricane Helene. The program has received generous support from various companies and individual donors to help cover expenses related to lost medications, housing, transportation, and personal essentials.

AUPH ARDX kidney patients hurricane disaster relief donations
Sentiment note

The article lists Aurinia Pharmaceuticals as one of the companies that have provided generous support to the American Kidney Fund's Disaster Relief Program, suggesting a positive sentiment towards their contribution.

Unknown Zacks Investment Research • Zacks Equity Research
Strength Seen in Aurinia (AUPH): Can Its 5.6% Jump Turn into More Strength?

Aurinia (AUPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

AUPH ESPR
Unknown Zacks Investment Research • Zacks Equity Research
How Much Upside is Left in Aurinia (AUPH)? Wall Street Analysts Think 96.51%

The average of price targets set by Wall Street analysts indicates a potential upside of 96.5% in Aurinia (AUPH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

AUPH
Unknown Zacks Investment Research • Zacks Equity Research
Aurinia Pharmaceuticals (AUPH) Reports Q1 Loss, Tops Revenue Estimates

Aurinia (AUPH) delivered earnings and revenue surprises of 82.35% and 8.65%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

AUPH CPRX
Unknown Benzinga • Avi Kapoor
Analog Devices To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Piper Sandler raised the price target for Wix.com Ltd. (NASDAQ: WIX) from $146 to $165. Piper Sandler analyst Clarke Jeffries maintained an Overweight rating. Wix.com shares rose 5.9% to close at $132.77 on Thursday. See how other analysts view this stock. Keybanc boosted Analog Devices, Inc. (NASDAQ: ADI) price target from $220 to $230. Keybanc analyst John Vinh maintained an Overweight rating. Analog Devices shares gained 2.3% to close at $193.72 on Wednesday. See how other analysts view this stock. Needham raised the price target for Glaukos Corporation (NYSE: GKOS) from $105 to $108. Needham analyst David Saxon maintained a Buy rating. Glaukos shares rose 0.7% to close at $92.79 on Wednesday. See how other analysts view this stock. TD Cowen raised Wingstop Inc. (NASDAQ: WING) ...Full story available on Benzinga.com

JACK UCTT ADI COTY News Price Target Small Cap Pre-Market Outlook
Unknown Benzinga • Avi Kapoor
Why Herbalife Shares Are Trading Lower By Around 36%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Shares of Herbalife Ltd. (NYSE: HLF) fell sharply in today’s session following weak quarterly earnings. Herbalife posted adjusted earnings of 28 cents per share, missing market estimates of 39 cents per share. The company’s quarterly sales came in at $1.22 billion versus expectations of $1.19 billion. Herbalife shares dipped 35.7% to $7.55 on Thursday. Here are some other stocks moving in today's mid-day session. Gainers JX Luxventure Limited (NASDAQ: JXJT) shares jumped 377% to $6.21 following H1 results. Dunxin Financial Holdings Limited (NYSE: DXF) surged 204% to $1.11 after gaining around 5% on Wednesday. China Natural Resources, Inc. (NASDAQ: CHNR) jumped 143% to $2.68 after gaining around 10% on Wednesday. The Children's Place, Inc. (NASDAQ: PLCE) rose 101% to $29.23. Nano-X Imaging Ltd. (NASDAQ: NNOX) shares climbed 54.7% to $9.84. Nvidia reported a 59,632 share stake in Nano X Imaging. RiskOn International, Inc. (NASDAQ: ROI) gained 54% to $0.1710. SoundHound AI, Inc. (NASDAQ: SOUN) gained 53% to $3.4499. According to data from Benzinga Pro, BlackRock reported a 5.6% passive stake in SoundHound AI after the market close. Traders also appear to be circling a filing from Nvidia in which the company disclosed positions in several companies, including SoundHound AI. Orgenesis Inc. (NASDAQ: ORGS) climbed 30.2% to $0.4362. Orgenesis 10% owner Jacob Safier acquired a total of 365,140 shares at an average price of $0.58. Pegasystems Inc. (NASDAQ: PEGA) jumped 27.8% to $64.84 after the company reported better-than-expected fourth-quarter financial results and issued FY24 EPS and revenue guidance above estimates. JFrog Ltd. (NASDAQ: FROG) shares gained 27% to $47.09 after the company reported better-than-expected fourth-quarter financial results and issued first-quarter adjusted EPS and revenue guidance above estimates. Infobird Co., Ltd (NASDAQ: IFBD) rose 26% to $1.1800. American Well Corporation (NASDAQ: AMWL) jumped 25% to $1.39 following quarterly results. Datasea Inc. (NASDAQ: DTSS) gained 25% to $11.24. DataSea announced a $30 million 5G multimodal communication technology service agreement. AppLovin Corporation (NASDAQ: APP) rose 22% to $57.16 after the company reported ...

ZBRA ORGS AMWL BMR News Penny Stocks Small Cap Intraday Update
Unknown Zacks Investment Research • Zacks Equity Research
Aurinia Pharmaceuticals (AUPH) Reports Q4 Loss, Tops Revenue Estimates

Aurinia (AUPH) delivered earnings and revenue surprises of -5.56% and 3.52%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

AUPH RXRX
Unknown Zacks Investment Research • Zacks Equity Research
Esperion Therapeutics (ESPR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Esperion Therapeutics (ESPR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ESPR AUPH
Unknown Zacks Investment Research • Zacks Equity Research
Aurinia Pharmaceuticals (AUPH) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Aurinia (AUPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AUPH
Unknown Zacks Investment Research • Zacks Equity Research
Are Medical Stocks Lagging Aurinia Pharmaceuticals (AUPH) This Year?

Here is how Aurinia Pharmaceuticals (AUPH) and Cardinal Health (CAH) have performed compared to their sector so far this year.

AUPH CAH
Unknown Zacks Investment Research • Zacks Equity Research
Is it a Good Idea to Buy Journey Medical (DERM) Stock Now?

Here, we discuss some reasons why investing in Journey Medical (DERM) stock now may turn out to be a prudent move.

NVO AUPH DERM ALPN
News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal